1. Home
  2. Directory
  3. New York
  4. Newburgh
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1902885387

JOSEPH ACCETTURA O.D
Prescription History 1902885387
Optometrist in Newburgh, NY

NPI Status: Active since January 12, 2006

Contact Information

1433 ROUTE 300 STE 108
NEWBURGH, NY
ZIP 12550
Phone: (845) 561-0305
Fax: (845) 561-9041

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JOSEPH ACCETTURA O.D, an active Optometrist specialist practicing in Newburgh, NY. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 60 documented patient claims. Among these therapy options, the most frequently utilized medication is Lumigan, which accounts for 34 claims alone.

Medication Index

L
X
No matching medications currently found on file.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 12
30-Day Fills 22.3
Days Supply 625
NY State Average Benchmarks
Peer Average Claims149.0
Peer Average 30-Day Fills254.5
Peer Average Days Supply7,268
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 91.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $237.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.76

State Avg Cost Per Claim

$20.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 34
30-Day Fills 37.7
Days Supply 917
NY State Average Benchmarks
Peer Average Claims77.0
Peer Average 30-Day Fills143.1
Peer Average Days Supply4,159
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.8% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,891.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$261.50

State Avg Cost Per Claim

$492.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Xiidra

Generic Formulation: LifitegrastSpecialty: Optometry
Provider Metrics Summary
Total Claims 14
30-Day Fills 30.0
Days Supply 900
NY State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills72.1
Peer Average Days Supply2,162
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,607.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,471.93

State Avg Cost Per Claim

$945.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JOSEPH ACCETTURA O.D provides transparency into local medical care patterns within Newburgh, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.